We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLGN:NYSESilgan Holdings Inc. Analysis

Data as of 2026-09-01 - not real-time

$41.54

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Silgan Holdings Inc. trades at $41.54, with its moving averages tangled rather than clearly stacked — a neutral trend structure. It has lost 9.8% over the past 30 days. Momentum indicators put RSI at 44.9 (neutral) with MACD reading bullish. Watch $40.23 as support and $43.56 as the nearer resistance level.
Multiples put this in undervalued territory at a P/E of 16.5. Sell-side targets cluster 33.1% above the current quote. Revenue is growing at 6.8% on a 4.0% profit margin. The 2.00% dividend yield looks covered by current payout levels.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 45.6%, a beta of 0.54 and a maximum drawdown of 25.9%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 4 out of 10.

Top Market Events

Silgan SLGN delivered earnings and revenue surprises of +2.Rigid packaging solutions manufacturer Silgan Holdings NYSE:SLGN reported Q2 CY2026 results , with sales up 6.Silgan SLGN doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Trading below the 200-day average of 41.84
  • MACD momentum is positive
  • 30-day price change of -9.8%

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Trading below the 200-day average of 41.84
  • Analyst targets imply +33.1% versus the current price
  • 30-day volatility of 45.6%

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Analyst targets imply +33.1% versus the current price
  • P/E ratio of 16.5
  • Elevated debt-to-equity of 203

Key Metrics & Analysis

Financial Health

Revenue Growth6.80%
Profit Margin4.04%
P/E Ratio16.5
ROE11.75%
ROA4.24%
Debt/Equity203.15
P/B Ratio1.8
Op. Cash Flow$640.8M
Free Cash Flow$313.3M

Technical Analysis

TrendNeutral
RSI44.9
Support$40.23
Resistance$43.56
MA 20$41.85
MA 50$43.70
MA 200$41.84
MACDBullish
VolumeStable
Fear & Greed Index94.79

Valuation

Fair Value$7.98
Target Price$55.31
Upside/Downside33.14%
GradeUndervalued
TypeBlend
Dividend Yield2.00%

Risk Assessment

Beta0.54
Volatility45.59%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.